

**Media Contact:**

Lynn Kieffer  
Vice President, Corporate Communications  
240-631-3391 • [kiefferl@ebsi.com](mailto:kiefferl@ebsi.com)

**Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA**

*112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threats*

**WHO:** [Emergent BioSolutions Inc.](#) (NYSE: EBS)

**WHAT:** Ribbon-cutting and tour of expanded Emergent BioSolutions' Center for Innovation in Advancement Development and Manufacturing (CIADM), featuring speakers:

***Daniel J. Abdun-Nabi***

President & Chief Executive Officer, Emergent BioSolutions

***Rick A. Bright, Ph.D.***

Director, Biomedical Advanced Research and Development Authority (BARDA)  
Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS)

***William H. Cole***

President & CEO, Baltimore Development Corporation

***Secretary Mike Gill***

Department of Commerce, State of Maryland

**WHY:** Five years ago, Emergent and BARDA entered into a public-private partnership to establish a CIADM intended to develop and manufacture medical countermeasures to protect the public in health emergencies.

This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM facility – one of only three HHS-designated Centers in the United States. The 112,000-square-foot facility, comprised of laboratory, manufacturing and office space, offers flexible manufacturing of drug substance from microbial, cell culture, or viral production platforms. Its capabilities for advanced development and manufacturing of medical countermeasures were designed to help address the U.S. government's national security and public health needs. The facility is equipped with disposable manufacturing technology to enable Emergent to meet the government's domestic preparedness priorities and needs on a cost-effective, reliable and sustainable basis.

Since its inception, the Emergent CIADM has been awarded four task orders by BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. Emergent has also successfully manufactured some of its product candidates at the CIADM and an Ebola vaccine candidate as part of a third-party collaboration.

**WHERE:** Emergent BioSolutions Bayview Campus  
5901 East Lombard St.  
Baltimore, MD 21224

**WHEN:** Wednesday, May 10, 2017  
9 a.m. to 11 a.m.

**About Emergent BioSolutions**

Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com). Follow us @emergentbiosolu.